Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ
16.86
-0.47 (-2.71%)
Closed
Oct 23, 2026
Day's Range
16.8117.31
52 wk Range
11.4819.25
Financial Statements - AUPH - Aurinia Pharmaceuticals Inc.
Revenue
283.05M▲ 20.4%
Net Income
287.20M▲ 4893.1%Net Margin 101.5%
EBITDA
139.58M▲ 154.6%
Free Cash Flow
135.40M▲ 207.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 283.05M | 235.13M | 175.51M | 134.03M | 45.60M | 50.11M |
| Cost of Goods | 32.66M | 28.24M | 14.14M | 5.66M | 1.09M | 0 |
| Gross Profit | 250.39M | 206.88M | 161.36M | 128.36M | 44.51M | 50.11M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 106.56M | 18.41M | -91.69M | -111.47M | -180.73M | -104.29M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -1.64M | -23.10M | - | - | - | -6.80M |
| Pre Tax Income | 114.15M | 7.44M | -77.46M | -106.35M | -180.20M | -102.77M |
| Income Tax | -173.04M | 1.69M | 551K | 1.82M | 760K | -94K |
| Net Income | 287.20M | 5.75M | -78.02M | -108.18M | -180.96M | -102.68M |
| EPS Basic | 2.14 | 0.04 | -0.54 | -0.76 | -1.4 | -0.87 |
| EPS Diluted | 2.07 | 0.04 | -0.54 | -0.76 | -1.4 | -0.87 |
| Basic Shares Outstanding | 134.36M | 143.05M | 143.23M | 141.91M | 129.36M | 118.47M |
| Diluted Shares Outstanding | 134.36M | 143.05M | 143.23M | 141.91M | 129.36M | 118.47M |
| Ebit | - | 12.28M | -74.69M | -106.35M | -180.20M | -104.29M |
| Ebitda | 139.58M | 54.83M | -63.04M | -103.64M | -177.44M | -102.91M |
| Net Income Continuous Operations | 287.20M | 5.75M | -78.02M | -108.18M | -180.96M | -102.68M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
